CFRX ContraFect Corporation

0.51
+0.02  (+5%)
Previous Close 0.49
Open 0.57
Price To Book 2.32
Market Cap 40,498,874
Shares 79,409,556
Volume 283,675
Short Ratio
Av. Daily Volume 650,230

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial noted clinically meaningful data but not statistically significant. Phase 3 trial planned.
CF-301
Serious infections caused byStaph aureus including MRSA

Latest News

  1. X-Biotix Therapeutics Joins Antimicrobials Working Group
  2. Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
  3. ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data
  4. Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
  5. ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
  6. ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
  7. ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
  8. CFRX: R&D Symposium Highlights Positive Data for Exebacase…
  9. ContraFect: 1Q Earnings Snapshot
  10. ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update
  11. ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease
  12. CFRX: Additional Phase 2 Data Presented at ECCMID…
  13. ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  14. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  15. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  16. ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
  17. ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  18. ContraFect Announces CEO Transition
  19. ContraFect to Present at the Bacteriophage Therapy Summit
  20. CFRX: Planning for Phase 3 Trial of Exebacase in S. Aureus Bacteremia…